calize the primary tumor as well as the recurrent and/ or the metastatic tumors. The ability of SRS to localize tumors depends on the subtype and the amount of somatostatin receptor (SSTR) expressed and the tumor size [4] .
We described herein a challenging case of ACTHdependent CS with discordant results of various endocrine and imaging tests. CT scan of the chest revealed two nodular lesions in the lung, one with uptake by [ 18 F]fluorodeoxy-glucose (FDG) positron emission tomography (PET) scan and another with uptake by SRS, while an equivocal small lesion was detected on pituitary MRI. Dynamic endocrine test revealed hyperresponse to corticotropin-releasing hormone (CRH) stimulation, but no suppression to high-dose dexamethasone, whereas positive ACTH gradient during inferior petrosal sinus sampling (IPSS) after CRH stimulation was consistent with the clinical diagnosis of Cushing's disease (CD). However, the resected lung tumor corresponding to the nodular lesion with a significant uptake by SRS was consistent with the diagnosis of bronchial carcinoid tumor causing EAS.
original [5] [6] [7] were synthesized by Greiner bio-one (Tokyo, Japan) ( Table 1 ). The PCR products were examined by 2% agarose gel electrophoresis. DNA contamination in the samples was examined by the parallel experiments without reverse transcriptase (RT).
Case Report
A 75-year-old woman with three-year history of diabetes and dyslipidemia was admitted to our hospital because of poor glycemic control. She had hypertension at the age of 71 and was treated with calciumchannel blocker (amlodipine), angiotensin receptor blocker (olmesartan) and β-blocker (bisoprolol), and had percutaneous coronary intervention for coronary heart disease a year earlier. On admission, she presented with Cushingoid features (moon facies, purpura and skin atrophy) and high blood pressure (145/79 mmHg), and was found to have osteoporosis. Laboratory examination revealed elevated fasting plasma glucose (184 mg/dL) and glycated hemoglobin (HbA1c: 8.1 %). She had markedly increased urinary free cortisol excretion (1706 μg/day), elevated levels of plasma ACTH (158 pg/mL), and serum cortisol (31.6 μg/dL). Plasma pro-GRP level (263 pg/mL), a neuroendocrine tumor marker, was elevated. Dynamic endocrine tests revealed lack of ACTH/cortisol circa-
methods

Immunohistochemical study
Immunohistochemical staining was performed on formalin-fixed, paraffin-embedded specimens of the resected tumor samples by the avidin-biotin-peroxidase complex (ABC) method using an auto-staining machine (Ventana Benchmark HX System, Ventana Medical System, Tucson, AZ, USA), according to the manufacturer's protocols. Primary antibodies used were mouse monoclonal anti-ACTH, anti-Ki-67, rabbit polyclonal anti-chromogranin A and anti-synaptophysin (Dako, Glostrup, Denmark).
Reverse transcription-polymerase chain reaction detection (RT-PCR)
Written informed consent for the analysis of the surgical tumor specimen was obtained from the patient. Total RNA was extracted from the resected tumor tissue using RNA zol (GIBCO/BRL, Carlsbad, CA), and cDNA synthesized using a First-Strand cDNA Syntheses Kit (Amersham Pharmacia Biotech Inc., NJ) according to the manufacturer's instructions. PCR primers of human proopimelanocortin (POMC), two splicing variants (gE, PX) in exon 3 [6] , CRH type 1 receptor (CRHR), arginine vasopressin receptor 1B (V1bR) and SSTR1-5 designed in earlier reports Circadian rhythm/DST and CRH were perfomed after cessation and 24 h withdrawal of hydrocortisone replacement (20mg/day), respectively. dian rhythm, no suppression to overnight high-dose (8 mg) dexamethasone suppression test (DST), hyperresponse to CRH stimulation, but not to desmopressin (DDAVP) stimulation (Table 2) . Subcutaneous administration of octreotide decreased plasma ACTH and cortisol levels ( Table 2) . These physical and endocrine data were consistent with a clinical diagnosis of ACTH-dependent CS.
To differentiate Cushing's disease (CD) from EAS, various imaging modalities were performed. CT scan of the chest (Fig. 1A) revealed two nodular lesions in the right lung; one in the middle lobe (S5) with a size of 5×6 mm and the other in the inferior lobe (S7) with a size of 17×8 mm. 18 F-FDG PET scan showed a slight uptake in the S5 lesion (Fig. 1B) , but not in the S7 lesion. SRS showed abnormal uptake of 111 In-pentetreotide only in the S7 lesion, but not in the S5 lesion (Fig. 1C ). Brain MRI (Fig. 2) showed an equivocal small non-enhanced area in the pituitary gland, suggestive of a microadenoma or cyst. IPSS showed a distinct ACTH gradient after CRH stimulation; central to peripheral (C/P) ratios of the right and the left IPS were 3.5 and 1.6, respectively (Table 2 ). These discordant results from the endocrine and imaging tests suggested either EAS by the pulmonary tumor in S7 and/ or pituitary microadenoma causing CD. Treatment with metyrapone (750 mg/day) and octreotide (200 μg/day) led to normalization of her plasma ACTH and cortisol levels (Fig. 3) .
Based on the positive result by SRS in combination with octreotide responsiveness and elevation of pro-GRP, the presumptive diagnosis of EAS seemed more likely than that of CD. After obtaining an informed consent from the patient, she underwent thoracoscopic partial resection of middle and inferior lobe of the right lung. Histopathologically, the resected tumor in S7 was consistent with the diagnosis of bronchial carcinoid tumor with positive immunostainings for ACTH and other neuroendocrine tumor markers (chromogranin A, synaptophysin) ( Fig. 4) with Ki-67 index (0.8 %), while the tumor in S5 was diagnosed with the pulmonary cryptococcosis. RT-PCR of the S7 tumor clearly showed increased expression of POMC (gE, PX) and SSTR (-1, -2, -4, -5) without DNA contamination (Fig. 5 ), but extremely low expression of V1bR and CRHR (data not shown). Postoperative course was uneventful, but replace- In-labeled pentetreotide; abnormal uptake in the S7 as indicated by arrows. ment with hydrocortisone (300 mg/day) was initiated, tapered and discontinued. Her postoperative plasma ACTH and cortisol levels became normalized ( Fig. 3) with complete suppression to overnight lowdose (1 mg) DST after cessation of replacement therapy, and normal response to CRH stimulation 24h after withdrawal of hydrocortisone (20 mg/day) ( Table 2) . Postoperative blood pressure was normalized without any medication, and her glycemic state was well controlled even after discontinuation of insulin. Two years after the surgery, she was free from tumor recurrence and hypercortisolism.
Discussion EAS, a rare cause of ACTH-dependent CS [8] , frequently presents a major diagnostic challenge because it is often indistinguishable from CD. Imaging studies are the cornerstone of EAS management because early localization, confirmation and surgical removal of the tumor constitute the curative treatment [9] . However, the tumors causing EAS are often too small and occult to be detected by conventional imaging modalities, such as CT and MRI scan [10] . Since a single positive finding may represent a false-positive result, combination of anatomical and functional imaging tests should be taken into account in such cases with a questionable, but equivocal tumor [11] .
It has been reported that FDG-PET for detection of the ectopic ACTH source has a sensitivity of 64% and positive predictive values of 53 % [2] . In this case, FDG-PET showed no significant uptake by the S7 tumor which was later identified as bronchial carcinoid tumor, but mild uptake by the S5 tumor which was found to be a cryptococcal granuloma. Since FDG-PET is known to identify tumors with high proliferative activities [12] , it is reasonable to assume that the granulomatous lung lesion seems metabolically-more active than bronchial carcinoid tumor with low Ki-67 index.
It has been reported that SRS for detection of the ectopic ACTH source have sensitivity of 57 % and positive predictive values of 79 % [2] . SRS using 111 In-pentetreotide is a useful tool to detect neuroendocrine tumors with abundant expression of SSTRs [13] , among which octreotide binds with higher affinity to SSTR-2 and SSTR-5. However, the expression pattern of SSTR subtype in bronchial carcinoid tumors have not yet been extensively investigated. In the present case, CT scan of the chest revealed two nodular lesions in the right lung (S5 and S7). Since administration of octreotide reduced plasma ACTH level, the presence of SSTR-2 and/or -5 in the ectopic ACTHproducing tumor is strongly suggested. In fact, SRS showed a significant uptake of radioactivity in the S7, but not in the S5 lesion, of the right lung, and the resected tumor in the S7 lesion expressed SSTR (-1, -2, -4, -5) mRNAs, but not SSTR-3 mRNA, as evaluated by RT-PCR.
In the present case, RT-PCR analyses also showed that the resected carcinoid tumor exhibited very low expressions of V1bR and CRHR mRNAs. The low V1bR expression is consistent with the lack of ACTH response to DDAVP stimulation, while the low CRHR expression excludes the possibility of ACTH secretion from the tumor by CRH. Although CRH test is currently considered as a reliable and noninvasive diagnostic test for the differential diagnosis of ACTHdependent CS, 30 % of patients with EAS exhibit false-positive results [14] .
IPSS with CRH stimulation has been regarded as the most accurate and reliable method to differentiate CD from EAS with high sensitivity (88-100 %) and specificity (90-100 %) [10, 15, 16] . A distinct gradient of the ACTH levels between the IPS and the peripheral veins with C/P ratios of ≥2.0 before and ≥3.0 after CRH stimulation, makes the definite diagnosis of CD. Although there are several possible causes of false-negative findings, including anatomical abnormalities, precluding satisfactory catheterization, false-positive cases have been rarely reported [17] . However, the present case showed a clear step-up (C/P ratio: 3.5) after CRH stimulation. Possible ectopic production of CRH by the same tumor was excluded by RT-PCR and immunohistochemical study (unpublished observation). The possible coexistence of subclinical CD could not be completely excluded in the present case because of the postoperative detectable plasma ACTH levels and the relatively short term (2 months) of glucocorticoid replacement. However, the results of the postoperative endocrine tests with normal circadian rhythm, complete suppression by overnight low-dose (1 mg) DST, and normal response to CRH stimulation all argue against this possibility. Thus, the positive result of IPSS and normal response to CRH stimulation in the present case may be partly explained by the unusual sensitivity of pituitary corticotroph to CRH, such as during the trough period of cyclic hormonogenesis by the tumor. In fact, such false-positive IPSS results have been reported in cases with EAS similar to ours [18, 19] .
In summary, we presented a diagnostic challenging case of EAS with pituitary and lung tumors indistinguishable from CD based on the results from various endocrine and imaging tests, among which SRS successfully localized the tumor responsible for the ectopic source of ACTH. SRS, although not approved in Japan yet, proves to be a useful tool to localize the ectopic ACTH source in such cases with multiple and/or questionable but equivocal tumors, thus warranting its utility as a diagnostic functional imaging modality to detect NETs.
